RESUMO
OBJECTIVE: To compare the therapeutic effects of donafinil and lenvatinib in the treatment of patients with intermediate--advanced hepatocellular carcinoma (HCC). METHODS: A total of 100 patients with intermediate--advanced HCC who received donafinib or lenvatinib treatment in Hechi First People's Hospital, Hechi People's Hospital, the Second Affiliated Hospital of Guangxi University of Science and Technology, and other centers from January 2021 to June 2022 were retrospectively analyzed. The patients were classified into a donafinil group (n=50) and a lenvatinib group (n=50) according to the treatment method. The therapeutic effects and adverse reactions of the two groups were compared, as well as the changes in alpha-fetoprotein (AFP), Golgi glycoprotein 73 (GP-73), and glypican-3 (GPC3) before and after treatment. RESULTS: The objective remission rate in the lenvatinib group was less than that in the donafenib group (20% VS 32%, P > 0.05). Disease control rates were higher in the donafinib group than in the lenvatinib group (70% VS 50%, P < 0.05). A comparison of survival time between the two groups showed that the survival rate and progression-free survival in the Donafenib group were higher than those in the Lunvatinib group (P < 0.05), and the main risk factor affecting the survival rate was the number of multiple tumors. There was no statistically significant difference in the rate of adverse reactions between the two groups (P > 0.05). The levels of AFP, GP-73, and GPC3 in the two groups were significantly lower than those before treatment (P < 0.05). CONCLUSION: Both donafenib and lenvatinib can effectively treat patients with middle and advanced hepatocellular carcinoma, and the local control rate of donafenib is higher than that of lenvatinib. The treatment of intermediate--advanced hepatocellular carcinoma patients with donafinib has better clinical efficacy than levatinib, which can effectively reduce the severity of patients' disease and prolong their survival time.
